[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543556":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":30,"responsibleParty":73,"collaborators":10,"id":76,"slug":10,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":10,"enrollmentInfo":85,"targetDuration":10,"studyType":88,"phases":10,"briefSummary":89,"conditions":90,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Medical University of Vienna","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intensive care unit patients",null,"Patients who are admitted to an participating intensive care unit who do not receive therapeutic anticoagulation.",[13],"Diagnostic Test: Anti-factor Xa activity calibrated for enoxaparin",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Anti-factor Xa activity calibrated for enoxaparin",[9],[20],{"name":21,"affiliation":5,"role":22},"Eva Schaden, MD","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},"Christoph Dibiasi, MD","CONTACT","0043 1 40400","41020","christoph.dibiasi@meduniwien.ac.at",[31,47,62],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Department of Internal Medicine, Medical University of Graz","RECRUITING","Graz","Styria","8063","Austria",{"type":39,"coordinates":40},"Point",[41,42],15.44197,47.06733,{"lat":42,"lon":41},[45],{"name":46,"role":26,"phone":10,"phoneExt":10,"email":10},"Philipp Eller, Prof.",{"facility":48,"status":33,"city":49,"state":50,"zip":51,"country":37,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck","Innsbruck","Tyrol","6020",{"type":39,"coordinates":53},[54,55],11.39454,47.26266,{"lat":55,"lon":54},[58],{"name":59,"role":26,"phone":60,"phoneExt":10,"email":61},"Michael Joannidis, Univ. Prof. Dr.","0043 512 9003 0","i-master@i-med.ac.at",{"facility":63,"status":33,"city":64,"state":10,"zip":65,"country":37,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna","Vienna","1090",{"type":39,"coordinates":67},[68,69],16.37208,48.20849,{"lat":69,"lon":68},[72],{"name":25,"role":26,"phone":10,"phoneExt":10,"email":10},{"type":22,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Eva Schaden","Assoc. Prof. Dr.","100543556",false,"NCT06357403","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients: a Prospective Multicentre Cohort Study","AntiXa-ICU","Inclusion Criteria:\n\n* Age over 18 years at the time of intensive care unit admission\n* Admission to a participating intensive care unit within the last 24 hours\n* Expected discharge is later than 48 hours after enrolment\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE\u002Fkg when given twice daily or of at least 150 IE\u002Fkg when given once daily\n* Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment\n* Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period\n* Estimated life expectancy below 48 hours or comfort terminal care order in place\n* Previously diagnosed heparin-induced thrombocytopenia\n* Pre-operative admission for elective surgery\n* Previous enrolment in the study","ALL","18 Years",{"count":86,"type":87},1300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and\u002For pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are:\n\n* What is the association between antiXa and VTE?\n* What is the association between antiXa and symptomatic, respectively incidental, VTE?\n* How is pharmacological anticoagulation with enoxaparin related to measured antiXa?\n* What is the association between antiXa and bleeding complications.\n* What is the incidence of venous thromboembolism in patients treated at an intensive care unit?\n* How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit\u002Fhospital.",[91,92,93],"Thrombosis","Pulmonary Embolism","Enoxaparin","2026-06-18",{"date":96,"type":97},"2026-06-23","ACTUAL",{"date":99,"type":97},"2024-05-04",{"date":101,"type":87},"2027-08",{"name":5,"class":6},3]